PIRS vs. AVTX, RDHL, MNPR, KPRX, PPBT, HUGE, EDSA, IMNN, ELAB, and AKTX
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include Avalo Therapeutics (AVTX), RedHill Biopharma (RDHL), Monopar Therapeutics (MNPR), Kiora Pharmaceuticals (KPRX), Purple Biotech (PPBT), FSD Pharma (HUGE), Edesa Biotech (EDSA), Imunon (IMNN), Elevai Labs (ELAB), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Pieris Pharmaceuticals (NASDAQ:PIRS) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
Pieris Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pieris Pharmaceuticals received 273 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 61.64% of users gave Pieris Pharmaceuticals an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
Pieris Pharmaceuticals has a net margin of -57.33% compared to Avalo Therapeutics' net margin of -1,639.50%. Pieris Pharmaceuticals' return on equity of -90.17% beat Avalo Therapeutics' return on equity.
40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Pieris Pharmaceuticals and Pieris Pharmaceuticals both had 3 articles in the media. Avalo Therapeutics' average media sentiment score of 1.59 beat Pieris Pharmaceuticals' score of 0.30 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
Pieris Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Summary
Pieris Pharmaceuticals beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
